TABLE 5.
Total number of BioFire PN panel detections for each analyte by specimen collection location and specimen type
| Target | No. (%) of detections in: |
|||||||
|---|---|---|---|---|---|---|---|---|
| BAL (n = 846) |
Sputum (n = 836) |
|||||||
| Hospitalized (n = 666) | Outpatient (n = 159) | ED (n = 21) | Total (n = 846) | Hospitalized (n = 682) | Outpatient (n = 73) | ED (n = 81) | Total (n = 836) | |
| Bacteria | ||||||||
| A. calcoaceticus-A. baumannii complex | 6 (0.9) | 0 (0) | 1 (4.8) | 7 (0.8) | 17 (2.5) | 6 (8.2) | 5 (6.2) | 28 (3.3) |
| E. cloacae complex | 22 (3.3) | 0 (0) | 1 (4.8) | 23 (2.7) | 25 (3.7) | 5 (6.8) | 2 (2.5) | 32 (3.8) |
| E. coli | 18 (2.7) | 0 (0) | 2 (9.5) | 20 (2.4) | 38 (5.6) | 2 (2.7) | 8 (9.9) | 48 (5.7) |
| H. influenzae | 61 (9.2) | 17 (10.7) | 4 (19.0) | 82 (9.7) | 84 (12.3) | 13 (17.8) | 10 (12.3) | 107 (12.8) |
| K. aerogenes | 12 (1.8) | 1 (0.6) | 0 (0) | 13 (1.5) | 10 (1.5) | 0 (0) | 2 (2.5) | 12 (1.4) |
| K. oxytoca | 10 (1.5) | 1 (0.6) | 0 (0) | 11 (1.3) | 14 (2.1) | 3 (4.1) | 2 (2.5) | 19 (2.3) |
| K. pneumoniae group | 23 (3.5) | 3 (1.9) | 1 (4.8) | 27 (3.2) | 54 (7.9) | 6 (8.2) | 5 (6.2) | 65 (7.8) |
| M. catarrhalis | 18 (2.7) | 11 (6.9) | 0 (0) | 29 (3.4) | 45 (6.6) | 16 (21.9) | 14 (17.3) | 75 (9.0) |
| Proteus spp. | 9 (1.4) | 0 (0) | 0 (0) | 9 (1.1) | 10 (1.5) | 5 (6.8) | 8 (9.9) | 23 (2.8) |
| P. aeruginosa | 58 (8.7) | 13 (8.2) | 3 (14.3) | 74 (8.7) | 106 (15.5) | 28 (38.4) | 26 (32.1) | 160 (19.1) |
| S. marcescens | 9 (1.4) | 2 (1.3) | 1 (4.8) | 12 (1.4) | 27 (4.0) | 10 (13.7) | 16 (19.8) | 53 (6.3) |
| S. aureus | 100 (15) | 10 (6.3) | 6 (28.6) | 116 (13.7) | 152 (22.3) | 26 (35.6) | 26 (32.1) | 204 (24.4) |
| S. agalactiae | 21 (3.2) | 3 (1.9) | 1 (4.8) | 25 (3.0) | 28 (4.1) | 7 (9.6) | 8 (9.9) | 43 (5.1) |
| S. pneumoniae | 21 (3.2) | 8 (5.0) | 0 (0) | 29 (3.4) | 35 (5.1) | 4 (5.5) | 12 (14.8) | 51 (6.1) |
| S. pyogenes | 5 (0.8) | 2 (1.3) | 1 (4.8) | 8 (0.9) | 8 (1.2) | 1 (1.4) | 2 (2.5) | 11 (1.3) |
| Antimicrobial resistance genes | ||||||||
| mecA/mecC and MREJ | 43 (6.5) | 1 (0.6) | 2 (9.5) | 46 (5.4) | 81 (11.9) | 14 (19.2) | 12 (14.8) | 107 (12.8) |
| KPC | 2 (0.3) | 0 (0) | 1 (4.8) | 3 (0.4) | 6 (0.9) | 1 (1.4) | 0 (0) | 7 (0.8) |
| NDM | 1 (0.2) | 0 (0) | 0 (0) | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| OXA-48-like | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| VIM | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.3) | 0 (0) | 0 (0) | 2 (0.2) |
| IMP | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| CTX-M | 7 (1.1) | 0 (0) | 0 (0) | 7 (0.8) | 6 (0.9) | 2 (2.7) | 1 (1.2) | 9 (1.1) |
| Atypical bacteria | ||||||||
| C. pneumoniae | 1 (0.2) | 0 (0) | 0 (0) | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| L. pneumophila | 2 (0.3) | 0 (0) | 0 (0) | 2 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| M. pneumoniae | 3 (0.5) | 1 (0.6) | 0 (0) | 4 (0.5) | 2 (0.3) | 0 (0) | 5 (6.2) | 7 (0.8) |
| Viruses | ||||||||
| Adenovirus | 7 (1.1) | 1 (0.6) | 0 (0) | 8 (0.9) | 12 (1.8) | 1 (1.4) | 3 (3.7) | 16 (1.9) |
| Coronavirus | 22 (3.3) | 9 (5.7) | 0 (0) | 31 (3.7) | 23 (3.4) | 8 (11) | 4 (4.9) | 35 (4.2) |
| Human metapneumovirus | 6 (0.9) | 2 (1.3) | 1 (4.8) | 9 (1.1) | 17 (2.5) | 1 (1.4) | 4 (4.9) | 22 (2.6) |
| Human rhinovirus/enterovirus | 47 (7.1) | 17 (10.7) | 0 (0) | 64 (7.6) | 69 (10.1) | 18 (24.7) | 25 (30.9) | 112 (13.4) |
| Influenza A virus | 13 (2.0) | 2 (1.3) | 0 (0) | 15 (1.8) | 9 (1.3) | 3 (4.1) | 4 (4.9) | 16 (1.9) |
| Influenza B virus | 6 (0.9) | 0 (0) | 1 (4.8) | 7 (0.8) | 11 (1.6) | 1 (1.4 | 2 (2.5) | 14 (1.7) |
| MERS-CoVa | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Parainfluenza virus | 17 (2.6) | 1 (0.6) | 0 (0) | 18 (2.1) | 25 (3.7) | 0 (0) | 5 (6.2) | 30 (3.6) |
| Respiratory syncytial virus | 4 (0.6) | 0 (0) | 0 (0) | 4 (0.5) | 38 (5.6) | 2 (2.7) | 8 (9.9) | 48 (5.7) |
a
MERS-CoV is reported only in the BioFire PNplus panel product.